See more : Newmont Corporation (0R28.L) Income Statement Analysis – Financial Results
Complete financial analysis of Addex Therapeutics Ltd (ADXN.SW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Addex Therapeutics Ltd, a leading company in the Biotechnology industry within the Healthcare sector.
- Net-a-Go Technology Company Limited (1483.HK) Income Statement Analysis – Financial Results
- Ascendant Digital Acquisition Corp. III (ACDI) Income Statement Analysis – Financial Results
- Isonics Corporation (ISON) Income Statement Analysis – Financial Results
- Jiangsu Holly Corporation (600128.SS) Income Statement Analysis – Financial Results
- Pop Mart International Group Limited (9992.HK) Income Statement Analysis – Financial Results
Addex Therapeutics Ltd (ADXN.SW)
About Addex Therapeutics Ltd
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.61M | 1.42M | 2.92M | 3.61M | 2.76M | 6.04M | 499.89K | 17.33K | 40.30K | 85.40K | 91.76K | 121.09K | 2.82M | 1.98M | 4.09M | 26.81M | 486.93K | 4.74M |
| Cost of Revenue | 6.93M | 14.62M | 12.82M | 10.37M | 230.10K | 144.17K | 29.76K | 17.33K | 40.30K | 85.40K | 91.76K | 1.27M | 27.99M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -5.32M | -13.20M | -9.90M | -6.76M | 2.53M | 5.90M | 470.13K | 0.00 | 0.00 | 0.00 | 0.00 | -1.15M | -25.16M | 1.98M | 4.09M | 26.81M | 486.93K | 4.74M |
| Gross Profit Ratio | -329.72% | -928.06% | -339.55% | -187.12% | 91.67% | 97.61% | 94.05% | 0.00% | 0.00% | 0.00% | 0.00% | -948.14% | -891.19% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 6.96M | 14.67M | 12.84M | 10.37M | 12.45M | 2.37M | 841.31K | 819.33K | 761.22K | 258.06K | 2.22M | 4.76M | 0.00 | 31.16M | 39.96M | 44.19M | 12.21M | 9.77M |
| General & Administrative | 7.20M | 7.30M | 5.14M | 5.15M | 4.27M | 4.72M | 2.20M | 1.52M | 1.57M | 1.55M | 6.47M | 12.85M | 6.73M | 6.43M | 7.60M | 7.55M | 0.00 | 0.00 |
| Selling & Marketing | -2.34M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.86M | 7.30M | 5.14M | 5.15M | 4.27M | 4.72M | 2.20M | 1.52M | 1.57M | 1.55M | 6.47M | 12.85M | 6.73M | 6.43M | 7.60M | 7.55M | 0.00 | 0.00 |
| Other Expenses | 0.00 | -22.52K | 444.00K | 336.68K | 648.17K | 382.99K | 197.67K | 799.70K | 311.82K | -9.44K | 5.77M | 9.40M | -919.55K | -2.02M | 0.00 | -67.33K | 25.90M | 15.98M |
| Operating Expenses | 11.89M | 21.94M | 18.42M | 15.86M | 17.37M | 7.47M | 3.24M | 3.14M | 2.64M | 1.80M | 14.46M | 27.01M | 5.81M | 35.57M | 47.56M | 51.68M | 38.11M | 25.76M |
| Cost & Expenses | 11.93M | 21.94M | 18.42M | 15.86M | 17.37M | 7.47M | 3.24M | 3.14M | 2.64M | 1.80M | 14.46M | 27.01M | 33.80M | 35.57M | 47.56M | 51.68M | 38.11M | 25.76M |
| Interest Income | 63.96K | 29.25K | 5.32K | 35.31K | 36.87K | 85.87K | 0.00 | 27.00 | 39.86K | 1.59K | 4.13K | 22.66K | 72.20K | 97.25K | 362.13K | 3.31M | 2.55M | 241.99K |
| Interest Expense | 21.61K | 48.90K | 63.01K | 69.50K | 128.52K | 220.17K | 45.35K | 6.92K | 152.21K | 0.00 | 0.00 | 0.00 | 239.37K | 144.81K | 0.00 | 501.88K | 8.54K | 30.45K |
| Depreciation & Amortization | 305.95K | 323.14K | 347.61K | 378.75K | 333.84K | 2.94K | 15.25K | 25.76K | 25.88K | 110.14K | 662.55K | 2.10M | 2.93M | 2.94M | 2.84M | 2.02M | 1.80M | 2.52M |
| EBITDA | -10.23M | -20.43M | -14.94M | -12.41M | -14.32M | -1.51M | -3.27M | -3.12M | -4.18M | -1.66M | -13.75M | -24.51M | -28.05M | -30.56M | -39.86M | -20.04M | -33.26M | -17.99M |
| EBITDA Ratio | -634.16% | -1,417.83% | -519.59% | -327.42% | -515.18% | -23.52% | -644.10% | -17,979.05% | -6,488.51% | -1,998.26% | -15,026.90% | -20,542.67% | -990.78% | -1,547.10% | 1,112.94% | -72.92% | -6,833.66% | -380.48% |
| Operating Income | -10.31M | -20.52M | -15.51M | -12.24M | -14.83M | -1.42M | -3.24M | -3.13M | -3.87M | -1.80M | -14.46M | -27.01M | -30.97M | -33.60M | -43.05M | -24.87M | -37.62M | -20.90M |
| Operating Income Ratio | -639.27% | -1,442.61% | -531.70% | -338.88% | -536.92% | -23.57% | -647.15% | -18,059.88% | -9,597.64% | -2,103.69% | -15,756.97% | -22,306.25% | -1,097.02% | -1,700.93% | -1,052.47% | -92.78% | -7,726.28% | -441.03% |
| Total Other Income/Expenses | -245.05K | -284.01K | 154.00K | -615.33K | -176.45K | -220.17K | -45.35K | -19.79K | -1.56M | 748.35K | -3.23K | -8.41K | -167.17K | -47.56K | 85.75M | 2.81M | 2.54M | 355.32K |
| Income Before Tax | -10.56M | -20.80M | -15.35M | -12.86M | -14.78M | -1.64M | -3.28M | -3.15M | -4.20M | -1.77M | -14.46M | -27.02M | -31.14M | -33.65M | 42.69M | -22.07M | -35.09M | -20.54M |
| Income Before Tax Ratio | -654.47% | -1,462.57% | -526.42% | -355.92% | -534.98% | -27.21% | -656.22% | -18,174.08% | -10,432.03% | -2,078.19% | -15,760.49% | -22,313.20% | -1,102.95% | -1,703.33% | 1,043.62% | -82.32% | -7,205.50% | -433.53% |
| Income Tax Expense | 0.00 | 264.36K | 63.01K | 69.50K | 128.52K | 1.00 | 0.00 | 6.92K | 152.21K | -21.68K | 3.23K | 8.41K | 72.20K | 97.25K | 171.54M | 3.31M | 2.54M | 463.91K |
| Net Income | -10.56M | -21.07M | -15.41M | -12.93M | -14.91M | -1.64M | -3.28M | -3.15M | -4.20M | -1.77M | -14.46M | -27.02M | -31.14M | -33.65M | -42.69M | -22.07M | -35.09M | -20.54M |
| Net Income Ratio | -654.47% | -1,481.16% | -528.58% | -357.84% | -539.63% | -27.21% | -656.22% | -18,174.08% | -10,432.03% | -2,078.19% | -15,760.49% | -22,313.20% | -1,102.95% | -1,703.33% | -1,043.62% | -82.32% | -7,205.50% | -433.53% |
| EPS | -0.14 | -0.47 | -0.45 | -0.48 | -0.56 | -0.07 | -0.25 | -0.28 | -0.39 | -0.18 | -1.60 | -3.41 | -4.19 | -5.69 | -7.44 | -3.85 | -6.99 | -7.19 |
| EPS Diluted | -0.14 | -0.47 | -0.45 | -0.48 | -0.56 | -0.07 | -0.25 | -0.28 | -0.39 | -0.18 | -1.60 | -3.41 | -4.19 | -5.69 | -7.44 | -3.85 | -6.99 | -7.19 |
| Weighted Avg Shares Out | 74.31M | 45.18M | 34.12M | 26.68M | 26.39M | 23.29M | 12.94M | 11.41M | 10.85M | 9.98M | 9.07M | 7.91M | 7.43M | 5.92M | 5.73M | 5.74M | 5.02M | 2.86M |
| Weighted Avg Shares Out (Dil) | 74.31M | 45.18M | 34.12M | 26.68M | 26.43M | 23.29M | 12.94M | 11.41M | 10.85M | 9.98M | 9.07M | 7.91M | 7.43M | 5.92M | 5.73M | 5.74M | 5.02M | 2.86M |
Source: https://incomestatements.info
Category: Stock Reports